Aptevo Therapeutics Inc. APVO
We take great care to ensure that the data presented and summarized in this overview for Aptevo Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APVO
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny517KShares$583,9710.0% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ349KShares$394,9020.93% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il262KShares$296,2000.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY159KShares$179,6690.0% of portfolio
-
Squarepoint Ops LLC New York, NY139KShares$156,7270.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny105KShares$118,2070.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA91.7KShares$103,6490.0% of portfolio
-
Armistice Capital, LLC New York, NY61.1KShares$69,0760.0% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY58.5KShares$66,1410.0% of portfolio
-
Black Rock Inc. New York, NY46.6KShares$52,6970.0% of portfolio
Latest Institutional Activity in APVO
Top Purchases
Top Sells
About APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Transactions at APVO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 04
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,584
+7.92%
|
-
|
Mar 03
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+8.91%
|
-
|
Mar 03
2024
|
Marvin L White President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,584
+12.44%
|
-
|
Mar 03
2024
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+13.23%
|
-
|
Mar 02
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+13.98%
|
-
|
Mar 02
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+17.89%
|
-
|
Mar 02
2024
|
Marvin L White President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,917
+18.25%
|
-
|
Mar 02
2024
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
3,667
+15.25%
|
-
|
Jan 29
2024
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
792
+5.68%
|
-
|
Jan 28
2024
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+6.08%
|
-
|
Jan 28
2024
|
Marvin L White President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,792
+9.64%
|
-
|
Aug 09
2023
|
Barbara Lopez Kunz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,571
+42.26%
|
-
|
Aug 09
2023
|
John Niederhuber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,571
+38.59%
|
-
|
Aug 09
2023
|
Daniel Abdun Nabi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,571
+29.98%
|
-
|
Aug 09
2023
|
Grady Grant Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,571
+42.26%
|
-
|
Aug 09
2023
|
Zsolt Harsanyi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,571
+29.64%
|
-
|
Aug 08
2023
|
Daphne Taylor SVP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+35.96%
|
-
|
Aug 08
2023
|
Jeffrey G. Lamothe EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,812
+19.58%
|
-
|
Aug 08
2023
|
So Young Kwon SVP, GC, BD & Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+35.94%
|
-
|
Jun 01
2023
|
John Niederhuber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+12.33%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 103K shares |
---|